We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current OXB market cap is 368.05M. The company's latest EPS is GBP -1.8414 and P/E is -2.00.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 64.06M | 87.73M | 142.8M | 139.99M | 89.54M |
| Operating Income | -12.84M | -5.49M | 20.82M | -51.56M | -84.96M |
| Net Income | -16.07M | -6.25M | 19.01M | -45.16M | -184.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 122.93M | 183.93M | 237.23M | 460.18M | 252.34M |
| Total Liabilities | 47.3M | 71.18M | 49.89M | 223.99M | 174.51M |
| Total Equity | 75.63M | 112.75M | 187.34M | 236.19M | 77.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -3.51M | 3.12M | 25.46M | -12.62M | -28.52M |
| Investing | -19.4M | -10.8M | -9.46M | -56.46M | 2.81M |
| Financing | 6.91M | 38.19M | 46.21M | 98.62M | -12.7M |
| Market Cap | 368.05M |
| Price to Earnings Ratio | -2.00 |
| Price to Sales Ratio | 4.11 |
| Price to Cash Ratio | 3.55 |
| Price to Book Ratio | 4.73 |
| Dividend Yield | - |
| Shares Outstanding | 100.01M |
| Average Volume (1 week) | 103.83k |
| Average Volume (1 Month) | 147.4k |
| 52 Week Change | -15.40% |
| 52 Week High | 460.00 |
| 52 Week Low | 164.40 |
| Spread (Intraday) | 3.5 (0.94%) |
| Company Name | Oxford Biomedica Plc |
| Address |
windrush court oxford OX4 6LT |
| Website | https://www.oxb.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
